CEA Industries Files Registration Statement for its $500M PIPE. CEO David Namdar Releases Letter to Shareholders
New York, Sept. 21, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (Nasdaq:…
ICEX and SOSA Launch Desafa San Francisco to Accelerate Spanish Startups in Silicon Valley
Credit: Maarten van den Heuvel // San Francisco, United States. MADRID, Sept.…
Tracer Launches Initial Exchange Offering on Coinstore: Building a Trusted RWA Ecosystem for Carbon Removal
Singapore, Sept. 20, 2025 (GLOBE NEWSWIRE) -- 15 September 2025 Singapore, Singapore…
Patients Taking AUSTEDO XR (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction
Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94%…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
PharmAla Files Amended and Restated Preliminary Base Shelf Prospectus
TORONTO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”…
Bravo Flowdex: How This Innovative Platform is Redefining AI Trading Read Bravo Flowdex Spain Report!
New York City, NY, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Introduction –…
Net Rowdex: Why Net Rowdex 2025 Emerges as a Next-Gen AI Trading Platform for Investors Read France Report!
New York City, NY, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Introduction to…
Immediate Edge: Exploring the AI Technology Behind Immediate Edge Trading Platform Germany Insights!
New York City, NY, Sept. 20, 2025 (GLOBE NEWSWIRE) -- Introduction to…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
